Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591774 | 0.87 | PRCP (0.42) | DRD2SLC18A3HTR1AHTR2ADRD3 | |
| SCHEMBL23664608 | 0.82 | HRH3 (0.41) | DRD2SLC18A3 | |
| SCHEMBL22965358 | 0.80 | CARM1 (0.45) | DRD2MEN1KMT2ASLC18A3HTR1A | |
| SCHEMBL23693482 | 0.80 | SIGMAR1 (0.51) | DRD2MEN1KMT2ASLC18A3PRCP | |
| SCHEMBL18592218 | 0.79 | DRD2 (0.40) | DRD2SLC18A3HTR1AHTR2ADRD3 | |
| SCHEMBL22537840 | 0.77 | DRD2 (0.51) | DRD2MEN1KMT2AHTR1AHTR2A | |
| SCHEMBL23692934 | 0.76 | SLC18A3 (0.64) | DRD2SLC18A3PRCPTLR9TLR8 | |
| SCHEMBL20004333 | 0.76 | DRD2 (0.54) | DRD2SLC18A3HTR1AHTR2ADRD3 | |
| SCHEMBL14923996 | 0.74 | DRD2 (0.54) | DRD2SLC18A3PRCPTLR9TLR8 | |
| SCHEMBL24295174 | 0.74 | DRD2 (0.38) | DRD2SLC18A3HTR1AHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | DRD2 3730/4885MEN1 562/4885KMT2A 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.